Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F16%3A00472127" target="_blank" >RIV/60077344:_____/16:00472127 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.bcp.2016.11.006" target="_blank" >http://dx.doi.org/10.1016/j.bcp.2016.11.006</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.bcp.2016.11.006" target="_blank" >10.1016/j.bcp.2016.11.006</a>
Alternative languages
Result language
angličtina
Original language name
Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis
Original language description
The molecular mechanisms behind the transition from simple steatosis to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) are not clearly understood. This hinders development of effective therapies for treatment and prevention of NASH. In this study expression profiling data from normal, steatosis, and NASH human livers were used to predict transcription factors that are misregulated as mechanistic features of NAFLD progression. Previously-published human NAFLD gene expression profiling data from normal, steatosis, and NASH livers were subjected to transcription factor binding site enrichment analysis. Selected transcription factors that bind enriched transcription factor binding sites were analyzed for changes in expression. Distinct transcription factor binding sites were enriched in genes significantly up- or down-regulated in NASH livers. Those enriched in up-regulated genes were bound by transcription factors such as FOXA, CEBP, and HNF1 family members, while those enriched in down-regulated genes were bound by nuclear receptors involved in xenobiotic sensing and lipid metabolism. Levels of mRNA and protein for selected transcription factors were significantly changed during disease progression. The study indicates that NAFLD progression involves changes in activity or expression of transcription factors that regulate genes involved in hepatic processes known to be altered in NASH. Transcription factors such as PPAR receptors, FoxA family members, and HNF4A might be targeted therapeutically to prevent NAFLD progression. (C) 2016 Elsevier Inc. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biochemical Pharmacology
ISSN
0006-2952
e-ISSN
—
Volume of the periodical
122
Issue of the periodical within the volume
December 15
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
62-71
UT code for WoS article
000390079200006
EID of the result in the Scopus database
2-s2.0-84997236626